Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Endpoint:
skin sensitisation: in vivo (LLNA)
Type of information:
experimental study
Adequacy of study:
key study
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
study well documented, meets generally accepted scientific principles, acceptable for assessment

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
2014
Report date:
2014

Materials and methods

Test guideline
Qualifier:
no guideline followed
Principles of method if other than guideline:
Evaluation is based on the ratio of T cells to B cells (CD3:CD19). This ratio is an indicator of the B cell proliferation induced by the treatment of mice with contact allergens. If the ratio of T cells to B cells is below 4, the test article is considered as a sensitizer.
GLP compliance:
not specified
Type of study:
mouse local lymph node assay (LLNA)

Test material

Constituent 1
Chemical structure
Reference substance name:
2-[(4-acetylnaphthalen-1-yl)formamido]-N-(2,2,2-trifluoroethyl)acetamide
EC Number:
807-880-2
Cas Number:
1125812-54-5
Molecular formula:
C17H15F3N2O3
IUPAC Name:
2-[(4-acetylnaphthalen-1-yl)formamido]-N-(2,2,2-trifluoroethyl)acetamide

In vivo test system

Test animals

Species:
mouse
Strain:
Balb/c
Sex:
female

Study design: in vivo (LLNA)

Vehicle:
dimethyl sulphoxide
Concentration:
50%
No. of animals per dose:
4
Details on study design:
25 µL to the dorsum of both ears on day 1, 2 and 3
Positive control substance(s):
other: DNCB

Results and discussion

In vivo (LLNA)

Results
Key result
Parameter:
other: Ratio CD3/CD19
Value:
6.8

Applicant's summary and conclusion

Interpretation of results:
GHS criteria not met
Conclusions:
The CD3/CD19 is higher than 4. The MR-008-4 intermediate has no sensitizing activity